Literature DB >> 28039159

Gut microbiota differs between children with Inflammatory Bowel Disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis.

Rebecca L Knoll1, Kristoffer Forslund2, Jens Roat Kultima2, Claudius U Meyer1, Ulrike Kullmer1, Shinichi Sunagawa2,3, Peer Bork2,4,5,6, Stephan Gehring7.   

Abstract

Current treatment for pediatric inflammatory bowel disease (IBD) patients is often ineffective, with serious side effects. Manipulating the gut microbiota via fecal microbiota transplantation (FMT) is an emerging treatment approach but remains controversial. We aimed to assess the composition of the fecal microbiome through a comparison of pediatric IBD patients to their healthy siblings, evaluating risks and prospects for FMT in this setting. A case-control (sibling) study was conducted analyzing fecal samples of six children with Crohn's disease (CD), six children with ulcerative colitis (UC) and 12 healthy siblings by metagenomic sequencing. In addition, lifetime antibiotic intake was retrospectively determined. Species richness and diversity were significantly reduced in UC patients compared with control [Mann-Whitney U-test false discovery rate (MWU FDR) = 0.011]. In UC, bacteria positively influencing gut homeostasis, e.g., Eubacterium rectale and Faecalibacterium prausnitzii, were significantly reduced in abundance (MWU FDR = 0.05). Known pathobionts like Escherichia coli were enriched in UC patients (MWU FDR = 0.084). Moreover, E. coli abundance correlated positively with that of several virulence genes (SCC > 0.65, FDR < 0.1). A shift toward antibiotic-resistant taxa in both IBD groups distinguished them from controls [MWU Benjamini-Hochberg-Yekutieli procedure (BY) FDR = 0.062 in UC, MWU BY FDR = 0.019 in CD). The collected results confirm a microbial dysbiosis in pediatric UC, and to a lesser extent in CD patients, replicating associations found previously using different methods. Taken together, these observations suggest microbiotal remodeling therapy from family donors, at least for children with UC, as a viable option.NEW &amp; NOTEWORTHY In this sibling study, prior reports of microbial dysbiosis in IBD patients from 16S rRNA sequencing was verified using deep shotgun sequencing and augmented with insights into the abundance of bacterial virulence genes and bacterial antibiotic resistance determinants, seen against the background of data on the specific antibiotic intake of each of the study participants. The observed dysbiosis, which distinguishes patients from siblings, highlights such siblings as potential donors for microbiotal remodeling therapy in IBD.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  fecal microbiota transplantation; inflammatory bowel diseases; metagenomics; microbiome; pediatric gastroenterology

Mesh:

Year:  2016        PMID: 28039159     DOI: 10.1152/ajpgi.00293.2016

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  25 in total

1.  Smarcad1 mediates microbiota-induced inflammation in mouse and coordinates gene expression in the intestinal epithelium.

Authors:  Juri Kazakevych; Jérémy Denizot; Anke Liebert; Mariana Portovedo; Mia Mosavie; Payal Jain; Claudia Stellato; Claire Fraser; Renan Oliveira Corrêa; Marina Célestine; Raphaël Mattiuz; Hanneke Okkenhaug; J Ross Miller; Marco Aurélio Ramirez Vinolo; Marc Veldhoen; Patrick Varga-Weisz
Journal:  Genome Biol       Date:  2020-03-11       Impact factor: 13.583

2.  The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease.

Authors:  Xinwei Xu; Dickson Kofi Wiredu Ocansey; Sanhua Hang; Bo Wang; Samuel Amoah; Chengxue Yi; Xu Zhang; Lianqin Liu; Fei Mao
Journal:  Gut Pathog       Date:  2022-06-21       Impact factor: 5.324

Review 3.  Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.

Authors:  Michael Kriss; Keith Z Hazleton; Nichole M Nusbacher; Casey G Martin; Catherine A Lozupone
Journal:  Curr Opin Microbiol       Date:  2018-07-20       Impact factor: 7.934

4.  Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.

Authors:  Fatouma Salem; Nadège Kindt; Julian R Marchesi; Patrick Netter; Anthony Lopez; Tunay Kokten; Silvio Danese; Jean-Yves Jouzeau; Laurent Peyrin-Biroulet; David Moulin
Journal:  United European Gastroenterol J       Date:  2019-08-01       Impact factor: 4.623

5.  16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis.

Authors:  Wenxuan Zuo; Beibei Wang; Xin Bai; Yihui Luan; Yingying Fan; Sonia Michail; Fengzhu Sun
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

Review 6.  Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention.

Authors:  Sai-Long Zhang; Shu-Na Wang; Chao-Yu Miao
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

7.  A roadmap towards personalized immunology.

Authors:  Sylvie Delhalle; Sebastian F N Bode; Rudi Balling; Markus Ollert; Feng Q He
Journal:  NPJ Syst Biol Appl       Date:  2018-02-06

8.  Draft Genome Sequences of Five Enterococcus Species Isolated from the Gut of Patients with Suspected Clostridium difficile Infection.

Authors:  Eduardo Castro-Nallar; Sandro L Valenzuela; Sebastián Baquedano; Carolina Sánchez; Fabiola Fernández; Annette N Trombert
Journal:  Genome Announc       Date:  2017-05-18

9.  Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions.

Authors:  Thao Pham; Harry Sokol; Bruno Halioua; Graziella Pourcel; Manuel Brun; Emilie Pain; Damien Testa
Journal:  BMC Nutr       Date:  2021-07-16

10.  Suppressed inflammation in obese children induced by a high-fiber diet is associated with the attenuation of gut microbial virulence factor genes.

Authors:  Hui Li; Guojun Wu; Liping Zhao; Menghui Zhang
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.